Introduction {#Sec1}
============

T cell immunodeficiencies have been observed in patients with hematological disorders \[[@CR1]\]. These deficiencies lead to the expansion of malignant clones and are thought to play an important role in tumorigenesis \[[@CR2]--[@CR5]\]. To design an effective approach for recovering T cell immunity, particularly antigen-specific T cell immunity, it is necessary to accurately evaluate the T cell immune status at either the molecular or cellular level, including characteristics such as recent thymic output function, number of naive T cells, diversity in the T cell receptor (TCR) repertoire, and tumor antigen-specific cytotoxicity T cell clones \[[@CR6]--[@CR9]\]. More recently, stem cell memory T (T~SCM~) cells have been described as a new immune biomarker for evaluating long-term memory T cell immune reconstitution, which is an important index after hematopoietic stem cell transplantation (HSCT) \[[@CR10]--[@CR12]\]. T~SCM~ cells have been shown to be able to differentiate into central memory T cells (T~CM~), effector memory (T~EM~), and terminal effector T cells (T~TE~).

Adaptive immunity is characterized by the ability to form long-lived immunological memory. Memory T cells develop when antigen-specific naive CD4^+^ or CD8^+^ T cells become activated upon antigen exposure and subsequently undergo proliferative expansion and differentiation \[[@CR13], [@CR14]\]. Therefore, efficient and persistent immune memory is essential for long-term protection against infections and malignancies. Memory T cells play a critical role in maintaining this immune defense \[[@CR15]\]. T~SCM~ cells are considered as an important immune marker for the repopulating T cell pool and immune reconstitution which is associated with favorable clinical outcome after HSCT \[[@CR16]\]. T~SCM~ cell research may support the advances in biomarker research, diagnosis, and therapy for hematological malignancies \[[@CR17]--[@CR20]\]. Moreover, T~SCM~ cell research may be important for understanding and influencing diverse chronic immune reactions, including graft-versus-host disease (GVHD) \[[@CR21]\].

T~SCM~ cell characteristics {#Sec2}
===========================

Memory T cells (including CD4^+^ and CD8^+^ memory T cells) include several subtypes: stem cell memory (T~SCM~), central memory (T~CM~), transitional memory (T~TM~) (described only in CD4^+^ memory T cells), effector memory (T~EM~), and terminal effector (T~TE~) T cells \[[@CR16], [@CR22]\]. T~SCM~ cells were first observed in a murine model of GVHD by Zhang et al., who reported a new subset of post-mitotic CD44^lo^CD62L^hi^CD8^+^ T cells expressing Sca-1 (stem cell antigen 1), CD122, and Bcl-2. This population of T cells was able to generate and sustain all allogeneic T cell subsets in GVHD reactions. These alloreactive CD8^+^ T cells were demonstrated to have enhanced self-renewal capacity and multipotency. These cells are capable of differentiating into T~CM~, T~EM~, and T~TE~ cells \[[@CR14], [@CR21]\]. In humans, an example came from the identification of a population of naive yellow fever (YF)-specific CD8^+^ T cells after vaccination. These cells were stably maintained for more than 25 years and were capable of ex vivo self-renewal. In-depth analysis of markers and genome-wide mRNA profiling have shown that these cells are distinct from genuine naive cells from unvaccinated donors and resemble the recently described stem cell-like memory subset T~SCM~ \[[@CR23]\]. Moreover, epigenetic analysis has also revealed that histone modifications and gene expression signatures could distinguish T~SCM~ from other CD8^+^ T cell subsets \[[@CR24]\]. Increasing data have supported the notion that the human T~SCM~ subset is a clearly distinct subset in between the naive T cell (T~N~) and T~CM~ subsets. Human T~SCM~ cells have been described as a long-lived memory T cell population which are CD45RO^−^, CCR7^+^, CD45RA^+^, CD62L^+^, CD27^+^, CD28^+^, and IL-7Rα^+^. These markers are characteristic of naive T cells. The immunophenotypic markers expressed in different T cell subtypes (from T~N~ to T~TE~ cells) are summarized in Table [1](#Tab1){ref-type="table"}. T~SCM~ cells express increased levels of CD95, IL-2Rβ, CXCR3, and LFA-1 and exhibit numerous functional attributes distinct from memory cells. However, human T~SCM~ cells constitute only approximately 2--4 % of the total CD4^+^ and CD8^+^ T cell population in the periphery and can be identified by polychromatic flow cytometry based on the simultaneous expression of several naive markers together with the memory marker CD95 \[[@CR25]\]. A linear T cell differentiation model and the minimum set of markers used for identifying and sorting T~SCM~ are depicted in Fig. [1](#Fig1){ref-type="fig"} \[[@CR25]\].Table 1Summary of the expression of functional molecules in circulating naive, memory T cell and terminal effector T cell subsetsSubsetPhenotypeT~N~CD45RO^−^CCR7^+^CD45RA^+^CD62L^+^CD27^+^CD28^+^CD127^+^(IL-7Rα^+^)CD95^−^CD103^−^T~SCM~CD45RO^−^CCR7^+^CD45RA^+^CD62L^+^CD27^+^CD28^+^CD127^+^(IL-7Rα^+^)CD95^+^CD103^−^T~CM~CD45RO^+^CCR7^+^CD45RA^−^CD62L^+^CD28^+^CD27^+^CD127^+^(IL-7Rα^+^)CD95^+^CD103^−^T~EM~CD45RO^+^CCR7^−^CD45RA^−^CD62L^−^CD28^−/+^CD27^−/+^CD127^−/+^(IL-7Rα^−/+^)CD95^+^CD103^+^T~TE~CD45RO^−^CCR7^−^CD45RA^+^CD62L^−^CD28^−/+^CD27^−^CD127^−^(IL-7Rα^−^)CD95^+^CD103^−^"*+*" positive expression, "*−*" negative expression, *T* ~*N*~ naive T cell, *T* ~*SCM*~ stem cell memory T cell, *T* ~*CM*~ central memory T cell, *T* ~*EM*~ effector memory T cell, *T* ~*TE*~ terminal effector T cellFig. 1Schematic model for T cell differentiation. Upon activation, naive T cells differentiate into various memory and effector cells. Self-renewal capacity, multipotency, and proliferation potential decrease upon differentiation. The expression of CD45R0, CCR7, CD28, and CD95 markers changes during T cell differentiation from T~N~ to T~TE.~ The minimum set of canonical markers can be used to identify the five major subsets of T cells. *T* ~*N*~ naive T cell, *T* ~*SCM*~ stem cell memory T cell, *T* ~*CM*~ central memory T cell, *T* ~*EM*~ effector memory T cell, *T* ~*TE*~ terminal effector T cell

Self-renewing memory T cells may be regulated by shared signaling pathways such as those involved in hematopoietic stem cells or memory B cells. The Wnt-β-catenin pathway is an evolutionarily conserved pathway that regulates hematopoietic stem cell self-renewal and multipotency by limiting stem cell proliferation and differentiation. Similarly, a key role for Wnt signaling during the maintenance of "stemness" in CD8^+^ T~SCM~ cells was demonstrated by Gattinoni et al. It was shown that disrupting the Wnt/β-catenin pathway by glycogen synthase-3β (GSK-3β) inhibitors promoted the generation of CD44^low^CD62L^high^Sca-1^high^CD122^high^Bcl-2^high^ self-renewing multipotent CD8^+^ T~SCM~ cells with proliferative and antitumor capacities that exceeded those of the T~CM~ and T~EM~ subsets \[[@CR11], [@CR26], [@CR27]\]. In addition, antigen-specific T~SCM~ cells were shown to preferentially reside in the lymph nodes (LNs) and less so in the spleen and bone marrow \[[@CR28]\].

There are numerous factors that act as modulators regulating the maturation and activation of CD8^+^ T cells, for example, suppressor of cytokine signaling (SOCS) is one of the key modulators \[[@CR29]\]. Moreover, it has been reported that activation of naive T cells with anti-CD3 and anti-CD28 antibody-conjugated beads in the presence of low doses of IL-7 and IL-15 promotes the generation of CD45RA^+^CD62L^+^CCR7^+^CD95^+^ T~SCM~ cells \[[@CR30]\].

Antigen-specific T~SCM~ {#Sec3}
=======================

It is well known that antigen-specific T cells are crucial components for antitumor or antivirus immunity in patients with hematological malignancies, particularly in patients after HSCT. It is possible that the number of antigen-specific T~SCM~ cells may be the determining factor of immunity. However, there have been few reports on antigen-specific T~SCM~ cells. Low frequency of these cells limits detailed characterization. For example, \<1 % of total human T cells are defined as CD8^+^CD45RA^+^CCR7^+^CD127^+^CD95^+^ viral-specific T~SCM~ cells. Human CMV-specific T~SCM~ cells can be detected at frequencies similar to those observed in other subsets, with frequency around ∼1/10,000 T cells \[[@CR31], [@CR32]\].

Antigen-specific T~SCM~ cells represent a long-lasting component of the cellular immune response to viruses and tumor-associated antigens (TAAs). For virus-specific T~SCM~ cells, research has first focused on human immunodeficiency virus type 1 (HIV-1)-specific CD8^+^ T~SCM~ cells. It is known that HIV-specific CD8^+^ T cells can influence HIV-1 disease progression during untreated HIV-1 infections, and recent data have shown that HIV-1-specific CD8^+^ T~SCM~ cells are detectable in all stages of HIV-1 infection. These cells were found to be increased in number in patients receiving suppressive antiretroviral therapy when compared with those untreated patients \[[@CR33]\]. It was found that CD4^+^ T~SCM~ cells were susceptible to HIV infection; thus, HIV-1 virus may exploit the stem cell characteristics of cellular immune memory T cells and lead to long-term viral persistence \[[@CR34]\]. Similar findings were demonstrated in a study of human T cell leukemia virus type 1 (HTLV-1)-infected CD4^+^ T~SCM~ cells in patients with adult T cell leukemia (ATL). This report first demonstrated an association between T cell malignancy and T~SCM~ cells. T~SCM~ cells from ATL patients were capable of sustaining themselves in a less proliferative mode, yet they were able to differentiate into other memory T cell populations during the rapidly propagating phase. These cells have been identified at the hierarchical apex capable of reconstituting identical ATL clones \[[@CR35]\]. A decrease in the infection of CD4^+^ T~SCM~ cells was found to preserve CD4^+^ T cell homeostasis and prevents disease progression despite significant viremia in both HIV-1 and HTLV-1 infections \[[@CR36]\].

T~SCM~ cells may play a major role in specific antitumor response and long-term immune surveillance directed against tumors \[[@CR17], [@CR37], [@CR38]\]. In addition, T~SCM~ cells have been proposed to be one of the key determinants of immune memory. It may be interesting to monitor the level of T~SCM~ cells and its significance for immune reconstitution and prognosis of patients with hematological malignancies before and after therapy, particularly HSCT. There have been only a few studies on TAA-specific T~SCM~ cells. Recently, dynamic changes of T~SCM~ cells were longitudinally tracked in patients who underwent haploidentical HSCT. These studies demonstrated that donor-derived T~SCM~ cells were highly enriched early after HSCT. T~SCM~ cells can differentiate directly from naive precursors infused in the grafts. Through T cell receptor (TCR) gene analysis, T~SCM~ cells have been found to have diversification in immune memory after allogeneic HSCT \[[@CR10]\]. It was also demonstrated that the level of T~SCM~ cells may be used to evaluate immune reconstitution in patients who received posttransplant cyclophosphamide (pt-Cy) for GVHD prophylaxis. Similarly, donor-derived T~SCM~ cells were found to be the most abundant circulating T cell population in the early days following haploidentical HSCT and pt-Cy. These donor-derived T~SCM~ cells preceded the expansion of effector cells. Antigen-specific T~SCM~ cells generated detectable recall responses; thus, it has been proposed to explore T~SCM~ cells derived from donor naive precursor cells in the clinical setting to overcome immunodeficiency \[[@CR12]\]. With the ability to expand and differentiate into effectors capable of mediating potent xenogeneic GVHD in immunodeficient mice, these donor naive precursor-derived T~SCM~ cells were noted to be superior to other memory lymphocytes. Furthermore, gene-modified T~SCM~ cells were found to be the only T cell subset capable of expanding and mediating GVHD in serial transplantations \[[@CR30]\]. These findings indicate negative aspects of T~SCM~ cells for clinical application.

The potential of T~SCM~ cells in immunotherapy for hematological malignancies {#Sec4}
=============================================================================

T~SCM~ cells may be a novel and critical therapeutic resource because these cells have the potential to serve as a stable cellular vehicle. Two gene therapy clinical trials with gene-corrected hematopoietic stem cells provided a glimpse into this possibility. Long-term in vivo T cell reconstitution was characterized in these trials. Specifically, the investigators traced the fate of greater than 1700 individual T cell clones in patients who underwent gene therapy. The studies demonstrated that the T~SCM~ cells persisted and preserved their precursor potential in humans for up to 12 years after the infusion of gene-corrected stem cells \[[@CR39]\]. The demonstration of the safe, functional, and decade-long survival of the engineered T~SCM~ cells in humans sets the stage for their clinical application. Since T~SCM~ cells were shown to be capable of reconstituting the full repertoire of memory and effector T cells after HSCT, it is particularly attractive to use them for adoptive immunotherapies. T~SCM~ cells might overcome current limitations, such as inefficient T cell engraftment, poor persistence, and inability to mediate prolonged immune attacks \[[@CR10]--[@CR12], [@CR40]\].

Even though potent antitumor activity of T~SCM~ cells was demonstrated in preclinical animal tumor models \[[@CR26], [@CR27]\], it is currently not feasible to treat patients with naturally occurring T~SCM~ cells because it is a scarce and small proportion of circulating lymphocytes. Therefore, strategies that can generate, expand, and enable the redirection of T~SCM~ cells against cancer cells need to be defined. Cieri and colleagues have recently described that a large number of T~SCM~ cells were generated by priming T cells with low doses of IL-7 and IL-15. It is therefore possible to generate, expand, and genetically engineer T~SCM~ cells in vitro from naive precursors. Furthermore, the in vitro-generated T~SCM~ cells displayed enhanced proliferative capacity upon adoptive transfer into immunodeficient mice, a finding consistent with those using naturally occurring T~SCM~ cells \[[@CR11], [@CR30]\]. T~SCM~ cells were also expanded from naive precursors by inhibiting Akt signaling during ex vivo priming and expansion. The Akt-inhibited minor histocompatibility antigen (MiHA)-specific CD8^+^ T cells had superior expansion capacity in vitro and induced superior antitumor activity in multiple myeloma-bearing immunodeficient mice. These findings provided a rationale for clinically exploiting ex vivo-generated, Akt-inhibited, MiHA-specific CD8^+^ T cells or TAA-specific CD8^+^ T cells for adoptive immunotherapy \[[@CR41], [@CR42]\]. Schmueck-Henneresse et al. also described a simplified culture protocol allowing for fast expansion of virus-specific T~SCM~ cells from a mixed T~N~/T~SCM~ pool of peripheral blood lymphocytes. This may be the basis for novel cell therapeutic options for life-threatening viral infections \[[@CR31]\]. Among the known memory T cell subpopulations, the T~SCM~ cell subset has profound implications for the design and development of effective vaccines as well as T cell-based therapies \[[@CR13], [@CR26], [@CR28]\]. As immunotherapy plays increasingly important roles in cancer management, further exploration of T~SCM~ cells and their regulation may facilitate clinical development of humoral (monoclonal antibodies and inhibitors of B cell receptor signaling) and cellular (CART) immunotherapies \[[@CR40], [@CR43]--[@CR47]\].

Conclusions and future perspectives {#Sec5}
===================================

T~SCM~ cells have the capacities of self-renewal and differentiation into various memory/effector subsets. These cells can lead to superior immune reconstitution. The identification of human T~SCM~ cells is directly relevant for evaluating life-long cellular immune status, immune reconstitution after allogeneic HSCT, and design of vaccines and T cell immunotherapy. However, it remains unclear at this time whether the number of T~SCM~ cells may be used as a standard biomarker for immune reconstitution after HSCT. In addition, the low number of T~SCM~ cells in circulating lymphocytes is also limiting their application \[[@CR11]\]. Strategies for in vitro and in vivo isolation and generation of highly effective antitumor T~SCM~ cells are under intensive investigation.
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